Business Context and Reporting Period
Company: Xeris Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Reporting Date: December 1, 2025
Business Context: The Company is a biopharmaceutical entity focused on developing novel therapeutics. This filing reports a specific regulatory milestone regarding intellectual property rather than periodic financial results.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material event reported is the issuance of a Notice of Allowance by the U.S. Patent and Trademark Office (USPTO) for the Company's XP-8121 patent application. This represents a significant advancement in the Company's intellectual property portfolio.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the patent allowance but does not include forward-looking guidance, financial outlook, or specific risk factors within the body of this report.
Unusual Items: None reported beyond the standard regulatory disclosure of the patent milestone.
Investor Verification Checklist
- Verify the scope and claims of the XP-8121 patent via the attached press release (Exhibit 99.1).
- Confirm the status of the patent issuance on the USPTO public database.
- Review the Company's most recent 10-K or 10-Q filings for current financial health, cash runway, and debt obligations, as this 8-K contains no financial data.
- Assess the commercial potential of the XP-8121 asset relative to the Company's overall pipeline strategy.